SOLASTA Bio secures patent and EPA approval
An agri-biotech firm says it has taken “one giant stride” in its route to market with major regulatory and intellectual property wins.
SOLASTA Bio, which develops nature-inspired bioinsecticides, has secured its first patent grant, reinforcing its technology for pest control using insect neuropeptides.
The Glasgow-based company has also received a crucial classification from the US Environmental Protection Agency, streamlining its regulatory path.
The milestones follow a $14 million funding round last year, with bosses saying they will help position SOLASTA Bio “exceptionally well” as it looks to commercialise its eco-friendly insecticides.
Shireen Davies, SOLASTA Bio co-founder and chief executive, said: “These developments represent a major inflection point.
“The combination of strong patent protection and a more efficient regulatory pathway positions us exceptionally well to advance our product development and reach full commercialisation within a few years.
“Our technology has the potential to transform the global crop protection market, and we are now one giant stride closer to realising that vision.”
Looking to promote your product/service to SME businesses in your region? Find out how Bdaily can help →
Enjoy the read? Get Bdaily delivered.
Sign up to receive our popular morning National email for free.
How businesses can reduce workplace safety risks with custom solutions
Tech firm unveils jobs plan after £530,000 backing
SMEs urged to think big at Newcastle event
B Corp is a commitment, not a one-time win
Government must get in gear on vehicle transition
A legacy in stone and spirit
Shaping the future: Your guide to planning reforms
The future direction of expert witness services
Getting people into gear for a workplace return
What to expect in the Spring Statement
Sunderland leading way in UK office supply market
Key construction developments in 2025